Danco Laboratories, the manufacturer of mifepristone, has appealed to the US Supreme Court seeking emergency relief from a recent Fifth Circuit Court of Appeals ruling that threatens nationwide access to the widely used abortion medication.

Fifth Circuit Ruling and Appeal

The appeal, filed Saturday, argues that the lower court’s decision is sweeping, dangerous, and creates significant legal uncertainty regarding the drug’s availability across the country. The company contends the ruling, stemming from a legal challenge initiated by the state of Louisiana, will leave medical providers, patients, and pharmacies unsure of what is permissible.

Request for Expedited Review

Danco specifically requests an immediate administrative stay of the Fifth Circuit’s ruling while the broader legal challenge progresses. They also urge the Supreme Court to expedite the case and hear it before the summer recess.

Impact on Access to Care

The Fifth Circuit’s decision has sparked widespread condemnation from reproductive rights advocates, who view it as a direct assault on women’s health and the fundamental right to choose. The ruling potentially disrupts access to mifepristone, used in approximately two-thirds of all pregnancy terminations in the United States.

Telehealth and Miscarriage Management

The decision also impacts access for those who rely on telehealth services, representing roughly a quarter of all patients. It restricts the use of telemedicine for prescribing mifepristone for other medical purposes, such as managing miscarriages.

Alternative Options and Concerns

While acknowledging the setback, medical and advocacy groups emphasize that misoprostol, another abortion pill, remains accessible via telehealth and can be used independently to terminate pregnancies. This is due to its broader medical applications, including treatment for ulcers and hemorrhage control.

Debunked Science and Political Motivations

Advocacy groups and legal experts have voiced strong concerns about the basis of the legal challenge, characterizing it as relying on debunked and flawed science. They assert that the safety of mifepristone, approved by the Food and Drug Administration (FDA) for over 25 years and used by more than 7 million people, has never been legitimately questioned.

Advocate Statements

Skye Perryman, CEO of Democracy Forward, emphasized the revolutionary impact of mail access to mifepristone, particularly for those in underserved areas. Mini Timmaraju, president and CEO of Reproductive Freedom for All, warned that the Fifth Circuit’s decision represents a significant step towards a national abortion ban.

Looking Ahead

The case is now poised to reach the Supreme Court, where reproductive rights advocates pledge to vigorously defend access to mifepristone. The outcome will have far-reaching consequences for reproductive healthcare access across the United States, potentially reshaping the landscape of abortion care for years to come.